Eli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales

What’s down the move: The pharmaceutical institution reported beardown income for its GLP-1 drugs Zepbound and Mounjaro, which are utilized for value absorption and diabetes.

Zepbound gross accrued 80% twelvemonth implicit twelvemonth to $4.16 billion, and Mounjaro gross soared 125% to $8.66 billion. Despite little prices for those drugs successful the US, beardown request helped assistance wide gross for the institution 56% twelvemonth implicit twelvemonth to $19.7 billion, meaning GLP-1s accounted for astir two-thirds of Eli Lilly’s full sales.

What other you request to know: Eli Lilly’s GLP-1 concern got different tailwind during the 4th with the FDA’s support of Foundayo, the pill mentation of its weight-loss drug.

“A cardinal milestone was the US FDA support of Foundayo — the lone approved GLP-1 pill that tin beryllium taken immoderate clip of day, without nutrient and h2o restrictions,” Lilly CEO David Ricks said.

Despite Thursday’s bump, shares of the drugmaker are down astir 13% twelvemonth to day arsenic increasing contention and pricing unit person weighed connected the stock.

Ines Ferre is simply a elder concern newsman for Yahoo Finance. Follow her connected X astatine @ines_ferre.

Click present for an in-depth investigation of the latest banal marketplace quality and events moving banal prices

Read the latest fiscal and concern quality from Yahoo Finance